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Replication of a distinct psoriatic arthritis risk
variant at the IL23R locus
Psoriatic arthritis (PsA) is a chronic inﬂammatory arthritis asso-
ciated with the presence of psoriasis. Although the majority of
PsA genetic risk loci identiﬁed also confer risk for psoriasis, the
difference in heritability between the two diseases suggests that
there remain uncovered risk loci that are associated with PsA
but not psoriasis (herein called PsA-speciﬁc loci).1 Here we
present an independent replication of a PsA-speciﬁc association
to rs12044149 at the well-established psoriasis risk locus,
IL23R, and conﬁrm its independence of the previously reported
psoriasis single-nucleotide polymorphism (SNP); rs9988642.2 3
Following quality control, genotype data were available for
Spanish, Cretan, German and UK PsA cases (914) and controls
(6945), independent of those tested previously2 for rs12044149
and rs9988642. All PsA case subjects were recruited from
rheumatology clinics and were diagnosed by a rheumatologist.
Genotype data were generated using the Life Technologies
TaqMan chemistry on the QuantStudio platform. Data were also
available for samples that had been previously genotyped. Case–
control association testing was performed separately for each
dataset using logistic regression in PLINK. This was followed by
a meta-analysis of the summary statistics, using an inverse-
variance ﬁxed-effects model (table 1). The association of
rs12044149 with PsA was replicated (p=4.03×10−6) and
remained signiﬁcant after including rs9988642 as a covariate
(pcond=4.86×10
−6). Meta-analysis of this data with that of our
previous Immunochip study reached genome-wide signiﬁcance
(pmeta=4.76×10
−20) in 2876 cases and 15 868 controls (table
1). For the previously reported psoriasis variant, rs9988642,3
only modest association was found with PsA in the replication
meta-analysis (p=0.04), and did not reach genome-wide signiﬁ-
cance upon meta-analysis of the combined PsA dataset
(p=4.61×10−4) (table 1).
We investigated differences between PsA and psoriasis by com-
bining our data with a subset of the psoriasis WTCCC2 study,4
excluding patients with known PsA (1784 psoriasis cases, 5175
controls). Here, rs9988642 was signiﬁcantly associated with
psoriasis (p=1.0×10−7) and remained so after conditioning for
rs12044149 (pcond=1.63×10
−5). The effect estimates of
rs12044149 for PsA and psoriasis were signiﬁcantly different
(p=2.0×10−3), when tested using multinomial logistic regression
in Stata. Direct comparison of the PsA and psoriasis genotypes
revealed a signiﬁcant association with an increased risk of PsA
with rs12044149 (p=4.52×10−4, OR=1.3). While we cannot
exclude the possibility of undiagnosed PsA cases in the psoriasis
group, their inclusion would have biased the results to the null
hypothesis of no difference in the association statistics between
PsA and psoriasis. These results support previously reported evi-
dence that the association signals for the IL23R variants
rs12044149 and rs9988642 are independent of each other and
that the association to rs12044149 is speciﬁc to PsA.2 5
A Bayesian reﬁnement method was applied to deﬁne credible
SNP sets based on each effect, as described previously.2 These
were localised to regulatory features using data from the
Roadmap Epigenomics Project6 and the online genetic and epi-
genetic ﬁnemapping data portal7 (ﬁgure 1). Credible SNPs
(n=13) for the PsA-speciﬁc associated SNP mapped to promoter
and enhancer regions within memory CD8+ T cells, which we
have previously reported to be critical for PsA.2 By contrast,
credible SNPs based on the psoriasis association (n=7) did not
overlap with regulatory elements and one, rs11209026, was
found to cause a missense mutation, resulting in an Arg381Gln
substitution.8 This could suggest the involvement of different
functional mechanisms for the PsA and psoriasis associations.
In conclusion, we have replicated a PsA-speciﬁc association at
the IL23R locus within an independent population, and conﬁrm
that the association with rs12044149 is distinct from the psoria-
sis IL23R variant, rs9988642. Currently, ﬁve robust PsA-speciﬁc
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Figure 1 (A) Association of IL23R variants in psoriatic arthritis (PsA)
Immunochip study (1962 cases, 8923 controls). (B) Association of IL23R
variants in psoriasis Immunochip study (2997 cases, 9183 controls).
Credible single-nucleotide polymorphism sets are depicted below each
plot for the rs12044149 (red) and rs9988642 (blue) association signals.
Table 1 Summary statistics for Immunochip, replication and meta-analysis of PsA and psoriasis variants at IL23R
Replication meta-analysis Immunochip Meta-analysis (All)
SNP Minor/major allele p Value OR I2 Q p Value OR p Value OR I2 Q
rs12044149 T/G 4.03E-06 1.33 10.15 0.34 2.25E-15 1.36 4.76E-20 1.35 0 0.49
rs9988642 C/T 0.04 0.78 34.51 0.21 4.51E-03 0.81 4.61E-04 0.80 13.76 0.33
I2, heterogeneity index for ORs; PsA, psoriatic arthritis; Q, Cochrane’s Q statistic for heterogeneity of ORs; SNP, single-nucleotide polymorphism.
Ann Rheum Dis July 2016 Vol 75 No 7 1417
Letters
 o
n
 23 July 2018 by guest. Protected by copyright.
http://ard.bmj.com/
Ann R
heum
 D
is: first published as 10.1136/annrheum
dis-2016-209290 on 25 M
arch 2016. Downloaded from
 
loci have been identiﬁed, including HLA-B,2 chromosome
5q31,2 PTPN229 and TNFAIP3.5 Such associations can provide
potential clinical beneﬁts in disease-risk estimation and linking
genetics with therapeutic targets.
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